larotrectinib (vitrakvi) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Larotrectinib (previously known as ARRY-470 and LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Larotrectinib is in phase II clinical trials for the treatment patients with solid tumors, non-Hodgkin lymphoma and for the pediatric patients with advanced solid or primary CNS tumors.   NCATS

Chemistry

  • SMILES: O[C@H]1CCN(C1)C(=O)Nc2cnn3ccc(nc23)N4CCC[C@@H]4c5cc(F)ccc5F
  • InChIKey: NYNZQNWKBKUAII-KBXCAEBGSA-N
  • Mol. Mass: 428.44
  • ALogP: 2.95
  • ChEMBL Molecules:
    larotrectinib  
    None  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$105.5080 - $541.2000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

arry-470 | larotrectinib | loxo-101 | n-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (41)

Approved Indications (1)


 

Neoplasms (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (41)


 

Bile Duct Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Diffuse Intrinsic Pontine Glioma (Early Phase 1)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 2)

Esophageal Neoplasms (Phase 2)

Fibrosarcoma (Phase 2)

Glioma (Phase 2)

Hepatoblastoma (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neuroblastoma (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Rhabdoid Tumor (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Skin Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Thyroid Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue